October 27, 2020

The Niche

Knoepfler lab stem cell blog

Cerebral Palsy

4 min read

The 60 Minutes show here in the U.S. has done sobering segments over the years on risky, unproven stem cell clinics, but now there is a new episode of 60 Minutes Australia that is the polar opposite: it mostly made a mess of things with its fluffy coverage of the story of a wonderful little girl with cerebral palsy receiving an unproven stem cell transplant at a clinic in Mexico. The new show segment, which you can watch in two parts (see below) on …Read More

3 min read

Some notable newly published Phase II data from the Duke cord blood for cerebral palsy trial unfortunately doesn’t give much reason for optimism that this approach is going to have a substantial positive effect for these kids. The double-blinded, placebo-controlled study did not find a meaningful benefit overall from infusions of autologous cord blood (ACB) for children with cerebral palsy. It didn’t meet its primary endpoint. The study was published in Stem Cells Translational Medicine and was entitled, “Effect of Autologous Cord Blood Infusion on Motor …Read More

4 min read

There is a critical need for treatments for children with autism. 2020 update: see this more recent post on my thinking on stem cells for autism. About a year ago I wrote about a clinical trial at Sutter Health in Sacramento that was approved by the FDA for stem cells for autism. At that time I was relatively less concerned about the trial. Over time, as I’ve learned more, I’ve gotten quite worried about it, a concern I discuss in my new book on …Read More

2 min read

The Korean-based stem cell biotech, RNL Bio, which also does business in the U.S. as RNL Bio and Human Biostar Inc, reportedly (seems to be a press release, PR) has filed an investigational new drug (IND) application with the Korean FDA (KFDA). The purpose of the application is to test the efficacy of autologous adult stem cells for the treatment of cerebral palsy. In the PR, it says the trial would treat up to 45 children using a product called RNL-AstrostemTM given intravenously (IV). By way of …Read More